Go Pro
→ The Starlink of Energy (From Monument Traders Alliance) (Ad)tc pixel Free VLG Stock Alerts

Venture Life Group (VLG) Competitors

Venture Life Group logo
GBX 69.30 -0.40 (-0.57%)
As of 11:25 AM Eastern
Compare

VLG vs. AGY, BXP, ANCR, BVXP, and EAH

Should you buy Venture Life Group stock or one of its competitors? MarketBeat compares Venture Life Group with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Venture Life Group include Allergy Therapeutics (AGY), Beximco Pharmaceuticals (BXP), Animalcare Group (ANCR), Bioventix (BVXP), and ECO Animal Health Group (EAH). These companies are all part of the "pharmaceuticals" industry.

How does Venture Life Group compare to Allergy Therapeutics?

Allergy Therapeutics (LON:AGY) and Venture Life Group (LON:VLG) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, risk, dividends, profitability, earnings, media sentiment, valuation and institutional ownership.

Venture Life Group has lower revenue, but higher earnings than Allergy Therapeutics. Allergy Therapeutics is trading at a lower price-to-earnings ratio than Venture Life Group, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Allergy Therapeutics£57.29M5.87-£52.59M-£0.97N/A
Venture Life Group£35.17M2.39£747.21K£4.3715.86

In the previous week, Allergy Therapeutics' average media sentiment score of 0.00 equaled Venture Life Group'saverage media sentiment score.

Company Overall Sentiment
Allergy Therapeutics Neutral
Venture Life Group Neutral

Allergy Therapeutics has a beta of 0.872, indicating that its stock price is 13% less volatile than the broader market. Comparatively, Venture Life Group has a beta of 0.217, indicating that its stock price is 78% less volatile than the broader market.

0.0% of Allergy Therapeutics shares are owned by institutional investors. Comparatively, 21.9% of Venture Life Group shares are owned by institutional investors. 3.6% of Allergy Therapeutics shares are owned by company insiders. Comparatively, 7.5% of Venture Life Group shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Venture Life Group has a net margin of 17.42% compared to Allergy Therapeutics' net margin of -85.46%. Allergy Therapeutics' return on equity of 409.00% beat Venture Life Group's return on equity.

Company Net Margins Return on Equity Return on Assets
Allergy Therapeutics-85.46% 409.00% -34.76%
Venture Life Group 17.42%7.82%1.56%

Summary

Venture Life Group beats Allergy Therapeutics on 7 of the 11 factors compared between the two stocks.

How does Venture Life Group compare to Beximco Pharmaceuticals?

Venture Life Group (LON:VLG) and Beximco Pharmaceuticals (LON:BXP) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, media sentiment, earnings, dividends, analyst recommendations, risk, valuation and institutional ownership.

Venture Life Group has a net margin of 17.42% compared to Beximco Pharmaceuticals' net margin of 16.76%. Beximco Pharmaceuticals' return on equity of 11.99% beat Venture Life Group's return on equity.

Company Net Margins Return on Equity Return on Assets
Venture Life Group17.42% 7.82% 1.56%
Beximco Pharmaceuticals 16.76%11.99%6.97%

21.9% of Venture Life Group shares are held by institutional investors. Comparatively, 0.3% of Beximco Pharmaceuticals shares are held by institutional investors. 7.5% of Venture Life Group shares are held by company insiders. Comparatively, 4.2% of Beximco Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Beximco Pharmaceuticals has higher revenue and earnings than Venture Life Group. Beximco Pharmaceuticals is trading at a lower price-to-earnings ratio than Venture Life Group, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Venture Life Group£35.17M2.39£747.21K£4.3715.86
Beximco Pharmaceuticals£53.93B0.00£970.84B£1.94 thousand0.03

Venture Life Group has a beta of 0.217, meaning that its share price is 78% less volatile than the broader market. Comparatively, Beximco Pharmaceuticals has a beta of 0.251, meaning that its share price is 75% less volatile than the broader market.

In the previous week, Beximco Pharmaceuticals had 1 more articles in the media than Venture Life Group. MarketBeat recorded 1 mentions for Beximco Pharmaceuticals and 0 mentions for Venture Life Group. Venture Life Group's average media sentiment score of 0.00 equaled Beximco Pharmaceuticals'average media sentiment score.

Company Overall Sentiment
Venture Life Group Neutral
Beximco Pharmaceuticals Neutral

Summary

Beximco Pharmaceuticals beats Venture Life Group on 7 of the 12 factors compared between the two stocks.

How does Venture Life Group compare to Animalcare Group?

Venture Life Group (LON:VLG) and Animalcare Group (LON:ANCR) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their earnings, risk, institutional ownership, profitability, valuation, analyst recommendations, media sentiment and dividends.

Venture Life Group has a beta of 0.217, indicating that its share price is 78% less volatile than the broader market. Comparatively, Animalcare Group has a beta of 0.67, indicating that its share price is 33% less volatile than the broader market.

Animalcare Group has higher revenue and earnings than Venture Life Group. Venture Life Group is trading at a lower price-to-earnings ratio than Animalcare Group, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Venture Life Group£35.17M2.39£747.21K£4.3715.86
Animalcare Group£89.11M2.60£36.55M£7.3045.89

In the previous week, Venture Life Group's average media sentiment score of 0.00 equaled Animalcare Group'saverage media sentiment score.

Company Overall Sentiment
Venture Life Group Neutral
Animalcare Group Neutral

21.9% of Venture Life Group shares are owned by institutional investors. Comparatively, 14.3% of Animalcare Group shares are owned by institutional investors. 7.5% of Venture Life Group shares are owned by insiders. Comparatively, 30.1% of Animalcare Group shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Venture Life Group has a net margin of 17.42% compared to Animalcare Group's net margin of 5.70%. Venture Life Group's return on equity of 7.82% beat Animalcare Group's return on equity.

Company Net Margins Return on Equity Return on Assets
Venture Life Group17.42% 7.82% 1.56%
Animalcare Group 5.70%4.46%2.97%

Summary

Animalcare Group beats Venture Life Group on 8 of the 11 factors compared between the two stocks.

How does Venture Life Group compare to Bioventix?

Bioventix (LON:BVXP) and Venture Life Group (LON:VLG) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, profitability, earnings, dividends, media sentiment, valuation, risk and institutional ownership.

Bioventix has a net margin of 59.30% compared to Venture Life Group's net margin of 17.42%. Bioventix's return on equity of 65.83% beat Venture Life Group's return on equity.

Company Net Margins Return on Equity Return on Assets
Bioventix59.30% 65.83% 54.07%
Venture Life Group 17.42%7.82%1.56%

20.6% of Bioventix shares are owned by institutional investors. Comparatively, 21.9% of Venture Life Group shares are owned by institutional investors. 6.2% of Bioventix shares are owned by insiders. Comparatively, 7.5% of Venture Life Group shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

In the previous week, Bioventix's average media sentiment score of 0.00 equaled Venture Life Group'saverage media sentiment score.

Company Overall Sentiment
Bioventix Neutral
Venture Life Group Neutral

Bioventix has a beta of 0.554, indicating that its stock price is 45% less volatile than the broader market. Comparatively, Venture Life Group has a beta of 0.217, indicating that its stock price is 78% less volatile than the broader market.

Bioventix has higher earnings, but lower revenue than Venture Life Group. Bioventix is trading at a lower price-to-earnings ratio than Venture Life Group, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Bioventix£12.54M6.25£8.12M£140.5210.67
Venture Life Group£35.17M2.39£747.21K£4.3715.86

Summary

Bioventix beats Venture Life Group on 7 of the 11 factors compared between the two stocks.

How does Venture Life Group compare to ECO Animal Health Group?

ECO Animal Health Group (LON:EAH) and Venture Life Group (LON:VLG) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, profitability, valuation, institutional ownership, earnings, dividends, risk and media sentiment.

ECO Animal Health Group has a beta of 0.71863484, meaning that its stock price is 28% less volatile than the broader market. Comparatively, Venture Life Group has a beta of 0.217, meaning that its stock price is 78% less volatile than the broader market.

40.8% of ECO Animal Health Group shares are held by institutional investors. Comparatively, 21.9% of Venture Life Group shares are held by institutional investors. 11.2% of ECO Animal Health Group shares are held by company insiders. Comparatively, 7.5% of Venture Life Group shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

ECO Animal Health Group currently has a consensus price target of GBX 160, indicating a potential upside of 56.86%. Given ECO Animal Health Group's stronger consensus rating and higher possible upside, research analysts clearly believe ECO Animal Health Group is more favorable than Venture Life Group.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
ECO Animal Health Group
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00
Venture Life Group
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

Venture Life Group has a net margin of 17.42% compared to ECO Animal Health Group's net margin of 2.50%. Venture Life Group's return on equity of 7.82% beat ECO Animal Health Group's return on equity.

Company Net Margins Return on Equity Return on Assets
ECO Animal Health Group2.50% 2.55% 2.14%
Venture Life Group 17.42%7.82%1.56%

ECO Animal Health Group has higher revenue and earnings than Venture Life Group. Venture Life Group is trading at a lower price-to-earnings ratio than ECO Animal Health Group, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ECO Animal Health Group£87.53M0.78£1.05M£3.1532.38
Venture Life Group£35.17M2.39£747.21K£4.3715.86

In the previous week, ECO Animal Health Group's average media sentiment score of 0.00 equaled Venture Life Group'saverage media sentiment score.

Company Overall Sentiment
ECO Animal Health Group Neutral
Venture Life Group Neutral

Summary

ECO Animal Health Group beats Venture Life Group on 10 of the 14 factors compared between the two stocks.

Get Venture Life Group News Delivered to You Automatically

Sign up to receive the latest news and ratings for VLG and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

VLG vs. The Competition

Export
MetricVenture Life GroupPharmaceuticals IndustryHealthcare SectorLON Exchange
Market Cap£84.07M£11.79B£6.93B£2.87B
Dividend Yield0.09%2.73%2.60%6.13%
P/E Ratio15.86794.01281.16369.49
Price / Sales2.39746.53576.6583,955.53
Price / Cash6.4072.4271.7927.89
Price / Book1.1810.7312.867.07
Net Income£747.21K£2.82B£3.49B£5.89B
7 Day Performance-0.57%2.88%2.65%1.18%
1 Month Performance5.00%-1.28%-2.63%0.90%
1 Year Performance8.17%195.94%76.00%75.31%

Venture Life Group Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
VLG
Venture Life Group
N/AGBX 69.30
-0.6%		N/A+7.3%£84.07M£35.17M15.86165
AGY
Allergy Therapeutics
N/AGBX 5.23
-12.6%		N/A-41.2%£330.94M£57.29MN/A612
BXP
Beximco Pharmaceuticals
N/AGBX 53.18
+0.3%		N/A+13.6%£237.24M£53.93B0.035,500
ANCR
Animalcare Group
N/AGBX 335
flat		N/AN/A£231.30M£89.11M45.89220
BVXP
Bioventix
N/AGBX 1,474.80
-2.1%		N/A-38.8%£77.06M£12.54M10.5012

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (LON:VLG) was last updated on 8/6/2026 by MarketBeat.com Staff.
From Our Partners
The Starlink of Energy
A portable energy unit - already used by the U.S. Navy for decades - is now drawing serious attention from Big...
Monument Traders Alliance | Sponsoredtc pixel
A Wall Street Veteran's Weekly Trade for Any Market Condition
Dave Aquino spent 25 years at Merrill Lynch and Vanguard studying one weekly options play that worked in bull,...
Base Camp Trading | Sponsoredtc pixel
Here’s the stock symbol I’ve promised
Whitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...
Stansberry Research | Sponsoredtc pixel
This AI fund sends investors payouts every Thursday
CrowdStrike, Palantir, Nvidia none of them pay a real dividend. But one fund holding the biggest AI names dist...
Investors Alley | Sponsoredtc pixel
This under $7 stock could be.
Just one mile from SpaceX's launchpad sits a small company doing something SpaceX can't - and it still trades ...
Freedom Financial | Sponsoredtc pixel
The dollar reset no one told you about
Porter Stansberry says a dollar reset is underway - one that has happened only once before in America's 250-ye...
Porter & Company | Sponsoredtc pixel
Buy this stock today
Marc Chaikin, founder of Chaikin Analytics, is sharing a strategy he calls 'Sell This, Buy That' - a way to mo...
Chaikin Analytics | Sponsoredtc pixel
Elon's new "super startup"
Adam O'Dell - the analyst who recommended Palantir before it became the top S&P 500 performer - has identified...
Banyan Hill Publishing | Sponsoredtc pixel